Deutsche Bank’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.03M Buy
162,758
+11,171
+7% +$266K ﹤0.01% 1411
2025
Q4
$3.54M Sell
151,587
-36,143
-19% -$805K ﹤0.01% 1482
2025
Q3
$3.7M Buy
187,730
+11,144
+6% +$229K ﹤0.01% 1451
2025
Q2
$3.83M Sell
176,586
-10,215
-5% -$241K ﹤0.01% 1357
2025
Q1
$4.53M Sell
186,801
-13,594
-7% -$306K ﹤0.01% 1290
2024
Q4
$4.18M Sell
200,395
-377,813
-65% -$8.12M ﹤0.01% 1422
2024
Q3
$11.5M Sell
578,208
-47,000
-8% -$871K ﹤0.01% 982
2024
Q2
$9.68M Sell
625,208
-1,045
-0.2% -$16.3K ﹤0.01% 1017
2024
Q1
$9.98M Buy
626,253
+7,167
+1% +$108K ﹤0.01% 1020
2023
Q4
$10.4M Buy
619,086
+512,829
+483% +$7.01M 0.01% 978
2023
Q3
$1.24M Sell
106,257
-854,991
-89% -$11.4M ﹤0.01% 1603
2023
Q2
$12.9M Buy
961,248
+26,510
+3% +$381K 0.01% 897
2023
Q1
$15.5M Sell
934,738
-146,710
-14% -$2.42M 0.01% 834
2022
Q4
$20.1M Sell
1,081,448
-62,203
-5% -$958K 0.01% 760
2022
Q3
$14.7M Buy
1,143,651
+1,094,054
+2,206% +$13M 0.01% 843
2022
Q2
$348K Sell
49,597
-3,686
-7% -$27K ﹤0.01% 2819
2022
Q1
$442K Sell
53,283
-5,840
-10% -$41.3K ﹤0.01% 2821
2021
Q4
$400K Buy
59,123
+3,101
+6% +$20.4K ﹤0.01% 2974
2021
Q3
$297K Sell
56,022
-1,793
-3% -$9.8K ﹤0.01% 3344
2021
Q2
$332K Sell
57,815
-9,841
-15% -$50.8K ﹤0.01% 3482
2021
Q1
$312K Sell
67,656
-5,906
-8% -$23.5K ﹤0.01% 3386
2020
Q4
$245K Buy
73,562
+15,712
+27% +$52.8K ﹤0.01% 3358
2020
Q3
$172K Buy
57,850
+5,798
+11% +$22.7K ﹤0.01% 3298
2020
Q2
$240K Sell
52,052
-435,255
-89% -$1.96M ﹤0.01% 3044
2020
Q1
$1.88M Sell
487,307
-2,272
-0.5% -$9.32K ﹤0.01% 1745
2019
Q4
$1.83M Buy
489,579
+461,609
+1,650% +$2.16M ﹤0.01% 2017
2019
Q3
$146K Sell
27,970
-58,142
-68% -$310K ﹤0.01% 3369
2019
Q2
$330K Sell
86,112
-38,148
-31% -$165K ﹤0.01% 3530
2019
Q1
$631K Sell
124,260
-1,804
-1% -$5.3K ﹤0.01% 3304
2018
Q4
$241K Sell
126,064
-201,570
-62% -$577K ﹤0.01% 3781
2018
Q3
$1.24M Buy
327,634
+132,621
+68% +$416K ﹤0.01% 3164
2018
Q2
$608K Sell
195,013
-568,963
-74% -$1.73M ﹤0.01% 3738
2018
Q1
$1.82M Buy
763,976
+101,474
+15% +$337K ﹤0.01% 2931
2017
Q4
$2.59M Buy
662,502
+216,095
+48% +$714K ﹤0.01% 2550
2017
Q3
$1.12M Sell
446,407
-206,204
-32% -$566K ﹤0.01% 2931
2017
Q2
$1.8M Buy
652,611
+515,823
+377% +$1.08M ﹤0.01% 2625
2017
Q1
$266K Buy
+136,788
New +$174K ﹤0.01% 3430
2016
Q4
Sell
-15,000
Closed -$16K 4933
2016
Q3
$16K Sell
15,000
-330,445
-96% -$298K ﹤0.01% 4585
2016
Q2
$245K Sell
345,445
-91,701
-21% -$73.9K ﹤0.01% 3664
2016
Q1
$510K Buy
437,146
+80,716
+23% +$125K ﹤0.01% 3202
2015
Q4
$872K Sell
356,430
-383,474
-52% -$1.1M ﹤0.01% 2967
2015
Q3
$2.22M Buy
739,904
+334,003
+82% +$1.44M ﹤0.01% 2416
2015
Q2
$1.68M Buy
405,901
+163,408
+67% +$651K ﹤0.01% 2604
2015
Q1
$1.05M Buy
242,493
+4,693
+2% +$16.9K ﹤0.01% 2854
2014
Q4
$706K Hold
237,800
﹤0.01% 3440
2014
Q3
$789K Buy
237,800
+187,800
+376% +$491K ﹤0.01% 3183
2014
Q2
$126K Hold
50,000
﹤0.01% 4417
2014
Q1
$113K Buy
+50,000
New +$105K ﹤0.01% 4175
2013
Q4
Sell
-47,529
Closed -$144K 5436
2013
Q3
$144K Buy
+47,529
New +$80K ﹤0.01% 4274

Other funds holding CPRX

Deutsche Bank's CPRX Position: Q1 2026 in Review

Deutsche Bank increased its Catalyst Pharmaceutical (CPRX) stake by 7.4% in Q1 2026, buying an estimated $266K and bringing the position to 162,758 shares worth $4.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1411.

Deutsche Bank first reported a position in CPRX in Q3 2013 and has held it in 49 quarters since. The position peaked at $20.1M in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Deutsche Bank held 162,758 shares of Catalyst Pharmaceutical worth $4.03M as of Q1 2026.
  • Deutsche Bank bought 11,171 Catalyst Pharmaceutical shares in Q1 2026, an estimated $266K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1411 holding.
  • Deutsche Bank first reported a position in Catalyst Pharmaceutical in Q3 2013 and has held it in 49 quarters since.
  • Deutsche Bank's Catalyst Pharmaceutical position peaked at $20.1M in Q4 2022.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.